会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • LOW-FRIABILITY, PATIENT-FRIENDLY ORALLY DISINTEGRATING FORMULATIONS
    • 低适应性,患者友好的ORALLY DISINC制剂
    • WO2007093305A3
    • 2008-01-24
    • PCT/EP2007001011
    • 2007-02-06
    • ANTARES PHARMA IPL AGGRENIER ARNAUDDECAUDIN CELINECARRARA DARIO NORBERTOCONTE UBALDOMAGGI LAURETTA
    • GRENIER ARNAUDDECAUDIN CELINECARRARA DARIO NORBERTOCONTE UBALDOMAGGI LAURETTA
    • A61K9/20
    • A61K9/0056A61K9/2018A61K9/2027A61K9/2095A61K31/78
    • The present invention relates to a rapidly disintegrating orally administratable solid dosage formulation that includes at least one active ingredient, at least one first disintegration agent that is at least one type-C methacrylic acid copolymer according to the U.S. Pharmacopoeia National Formulary US/NF, a second disintegration agent of crospovidone or a cross-linked povidone polymer derivative thereof, and a non-cariogenic diluent that does not increase glucose blood levels. The at least one first disintegration agent does not function as an enteric coating, insulation coating intended to protect active ingredient(s), or coating intended to mask taste or smell. The solid dosage form has a mass of about 50 to about 1000 mg, and the at least one first disintegration agent is present in the dosage form in an amount not exceeding 15%, with respect to the total weight of the dosage form. The second disintegration agent is present in the dosage form in an amount not exceeding 15% with respect to the total weight of the dosage form. The first and the second disintegration agent are present in total amounts that provide a weight ratio of about 1 : 1 to about 1:3, wherein the dosage form provides at least one of the in vitro or in vivo disintegration time that is less than 30 seconds, and has a friability of 1% or less according to the U.S. Pharmacopoeia test.
    • 本发明涉及快速崩解的可口服给药的固体剂型制剂,其包含至少一种活性成分,至少一种第一崩解剂,其是根据US Pharmacopoeia National Formulary US / NF至少一种C型甲基丙烯酸共聚物, 交联聚维酮的第二崩解剂或其交联聚维酮聚合物衍生物和不增加葡萄糖血液水平的非致龋剂稀释剂。 至少一种第一崩解剂不用作肠溶衣,旨在保护活性成分的绝缘涂层或旨在掩蔽味道或气味的涂层。 相对于剂型的总重量,固体剂型具有约50至约1000mg的质量,并且至少一种第一崩解剂以不超过15%的量存在于剂型中。 相对于剂型的总重量,第二崩解剂以不超过15%的量存在于剂型中。 第一和第二崩解剂以提供重量比为约1:1至约1:3的总量存在,其中该剂型提供至少一种体外或体内崩解时间小于30 秒,根据美国药典测试,其脆度为1%以下。